Heartflow (HTFL) announced it has received FDA 510 clearance for its Next Gen Heartflow Plaque Analysis algorithm and the platform is now available. The technology features an updated algorithm, vastly expanded nomogram, and advanced 3D color-coded visualization of plaque type, volume, and distribution, empowering clinicians with the insights needed to make confident care decisions with ease. Heartflow also announced that Heartflow Plaque Analysis will be covered by Cigna (CI) across all of its lines of business, including Commercial and Medicare Advantage plans, beginning in October.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HTFL:
- Heartflow price target raised to $39 from $35 at Canaccord
- HeartFlow, Inc.: Balancing Impressive Growth with Strategic Challenges – A Hold Recommendation
- HeartFlow Releases Investor Presentation at Healthcare Conference
- Elf Beauty downgraded, Zscaler upgraded: Wall Street’s top analyst calls
- Heartflow initiated with an Equal Weight at Morgan Stanley